Advantar & DavosPharma ally to broaden service offering

By Nick Taylor

- Last updated on GMT

Related tags Pharmacology Monoclonal antibodies

Advantar Labs has allied with DavosPharma to accelerate clients’ development programmes with chemistry and analytical services.

Inking the non-exclusive strategic alliance broadens both companies’ service offering. California-based Advantar Labs expects to quicken drug development for its clients, primarily small to mid-size biopharm, by having access to the extra services.

For time critical studies, we are able to utilise DavosPharma’s infrastructure and broad network to provide more options and overall guidance to customers for their development needs​”, Rich Kenley, CEO of Advantar Labs, said.

New Jersey-based DavosPharma provides custom intermediates, active pharmaceutical ingredients (API) and dosage forms, along with medicinal chemistry and biology discovery services. Allying with Advantar Labs gives DavosPharma access to clinical packaging, stability testing and other services.

[Advantar] has a tremendous breadth of analytical and formulation development experience. Finding the right partner with the compliance, analytical resources and communication we need, is no easy feat​”, Giff Marzoni, vice president of global API development at DavosPharma, said.

By allying the companies hope to gain an edge over other contract research organisations (CRO). “[This deal] puts our lab well ahead of many competing CRO’s with in-house project management, because they often lack specific area expertise or comprehensive tracking tools​”, Kenley said.

An earlier partnership

DavosPharma’s agreement with Advantar Labs follows a similar strategic alliance with Immunologix. In May DavosPharma inked the deal to gain access to technology for producing antigen-targeting human monoclonal antibodies from naïve B-cells.

The partnership allows both parties to offer their clients a platform to 100 per cent human monoclonal antibody ready for clinical trials. It will help in bringing our game changing technology to the pharmaceutical marketplace​”, Ryan Fiorini, chief operating officer at Immunologix, said.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers